QuidelOrtho (QDEL) Cash & Equivalents (2021 - 2026)

QuidelOrtho's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $140.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 10.46% year-over-year to $140.4 million; the TTM figure through Mar 2026 stood at $140.4 million (up 10.46% YoY), while the FY2025 annual figure was $169.8 million, up 72.74% from the prior year.
• Cash & Equivalents came in at $140.4 million for Q1 2026 at QuidelOrtho, down from $169.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.3 billion in Q2 2022 to a low of $79.0 million in Q1 2024.
• A 5-year average of $271.4 million and a median of $150.8 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 77.74% in 2024 and surged 72.74% in 2025, its largest moves.
• QuidelOrtho's Cash & Equivalents stood at $213.2 million in 2022, then tumbled by 43.95% to $119.5 million in 2023, then retreated by 17.74% to $98.3 million in 2024, then soared by 72.74% to $169.8 million in 2025, then declined by 17.31% to $140.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $140.4 million, $169.8 million, and $98.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison